Biodexa Pharmaceuticals (BDRX)
Biodexa Pharmaceuticals Statistics
Share Statistics
Biodexa Pharmaceuticals has 1.67K shares outstanding. The number of shares has increased by 145.69% in one year.
| Shares Outstanding | 1.67K |
| Shares Change (YoY) | 145.69% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 15.07M |
| Failed to Deliver (FTD) Shares | 484 |
| FTD / Avg. Volume | 0.03% |
Short Selling Information
The latest short interest is 68.47K, so 10.24% of the outstanding shares have been sold short.
| Short Interest | 68.47K |
| Short % of Shares Out | 10.24% |
| Short % of Float | 10.24% |
| Short Ratio (days to cover) | 1 |
Valuation Ratios
The PE ratio is 0 and the forward PE ratio is null. Biodexa Pharmaceuticals's PEG ratio is 0.
| PE Ratio | 0 |
| Forward PE | n/a |
| PS Ratio | 0 |
| Forward PS | 0.8 |
| PB Ratio | 0 |
| P/FCF Ratio | 0 |
| PEG Ratio | 0 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Biodexa Pharmaceuticals.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.75, with a Debt / Equity ratio of 0.09.
| Current Ratio | 1.75 |
| Quick Ratio | 1.75 |
| Debt / Equity | 0.09 |
| Debt / EBITDA | -0.1 |
| Debt / FCF | -0.06 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $29.31K |
| Profits Per Employee | $-544.54K |
| Employee Count | 13 |
| Asset Turnover | null |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -406K |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -92.27% in the last 52 weeks. The beta is 1.71, so Biodexa Pharmaceuticals's price volatility has been higher than the market average.
| Beta | 1.71 |
| 52-Week Price Change | -92.27% |
| 50-Day Moving Average | 2.42 |
| 200-Day Moving Average | 7.3 |
| Relative Strength Index (RSI) | 39.16 |
| Average Volume (20 Days) | 1.93M |
Income Statement
In the last 12 months, Biodexa Pharmaceuticals had revenue of 381K and earned -7.08M in profits. Earnings per share was -224.13.
| Revenue | 381K |
| Gross Profit | -3.69M |
| Operating Income | -8.01M |
| Net Income | -7.08M |
| EBITDA | -7.16M |
| EBIT | -7.44M |
| Earnings Per Share (EPS) | -224.13 |
Balance Sheet
The company has 1.67M in cash and 727K in debt, giving a net cash position of 942K.
| Cash & Cash Equivalents | 1.67M |
| Total Debt | 727K |
| Net Cash | 942K |
| Retained Earnings | -150.42M |
| Total Assets | 14.78M |
| Working Capital | 3.78M |
Cash Flow
In the last 12 months, operating cash flow was -12.26M and capital expenditures -774K, giving a free cash flow of -13.04M.
| Operating Cash Flow | -12.26M |
| Capital Expenditures | -774K |
| Free Cash Flow | -13.04M |
| FCF Per Share | 0 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | -2103.41% |
| FCF Margin | -3421.26% |
Dividends & Yields
BDRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
Currently there are no analyst rating for BDRX.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on Oct 4, 2024. It was a backward split with a ratio of 1:25.
| Last Split Date | Oct 4, 2024 |
| Split Type | backward |
| Split Ratio | 1:25 |
Scores
| Altman Z-Score | -17.16 |
| Piotroski F-Score | 0 |